Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H11F3N2O4 |
Molecular Weight | 292.2112 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(O)C(=O)NC1=CC=C(C(=C1)C(F)(F)F)[N+]([O-])=O
InChI
InChIKey=YPQLFJODEKMJEF-UHFFFAOYSA-N
InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)
Molecular Formula | C11H11F3N2O4 |
Molecular Weight | 292.2112 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Hydroxyflutamide is the major active metabolite of flutamide. Flutamide undergoes extensive first-pass metabolism by CYP1A2 to its metabolite hydroxyflutamide and its hydrolysis product, 3-trifluoromethyl-4-nitroaniline. Hydroxyflutamide is a more powerful antiandrogen in vivo, with higher affinity for the receptor than that of flutamide. Hydroxyflutamide is in phase II clinical trials for the treatment of prostate cancer. However, a drug resistance problem appears after about one year's treatment. Per-residue free energy decomposition analyses indicate that N705, T877, and M895 androgen receptor mutations are vital residues in the agonist/antagonist mechanism of hydroxyflutamide.
Approval Year
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 25.1189 uM] | ||||
no [Activation 25.1189 uM] | ||||
no [IC50 39.8045 uM] | ||||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. | 1998 May 1 |
|
Regulation of GCDFP-15 expression in human mammary cancer cells. | 1999 Aug |
|
Role of cadmium in the regulation of AR gene expression and activity. | 2002 Jan |
|
Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. | 2002 Mar |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism. | 2008 Apr |
|
Characterization of steroid hormone receptor activities in 100 hydroxylated polychlorinated biphenyls, including congeners identified in humans. | 2011 Nov 18 |
|
Ligand-independent androgen receptor antagonism caused by the newly developed pesticide pyrifluquinazon (PFQ). | 2013 Jan |
|
Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and Its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips. | 2013 Mar |
|
The brominated flame retardants TBP-AE and TBP-DBPE antagonize the chicken androgen receptor and act as potential endocrine disrupters in chicken LMH cells. | 2015 Dec |
|
Low dose evaluation of the antiandrogen flutamide following a Mode of Action approach. | 2015 Dec 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00913263
Single injection in one lobe of 2-8 mL ready-made paste (corresponding to 400-1600 mg 2-Hydroxyflutamid)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23889773
The dihydrotestosterone-mediated induction of Amyloid precursor protein (APP) mRNA expression was potently suppressed by 10 uM of an androgen receptor blocker hydroxyflutamide (0.35-fold and P<0.01, compared to a group treated by DHT alone), whereas hydroxyflutamide alone did not significantly alter APP mRNA level in MCF-7cells (0.79-fold, P=0.69).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 00:32:21 GMT 2023
by
admin
on
Sat Dec 16 00:32:21 GMT 2023
|
Record UNII |
31D90UKP5Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C146993
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000042596
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY | |||
|
52806-53-8
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY | |||
|
C63948
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY | |||
|
31D90UKP5Y
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY | |||
|
91649
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY | |||
|
C014290
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY | |||
|
Hydroxyflutamide
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY | |||
|
DTXSID8033562
Created by
admin on Sat Dec 16 00:32:21 GMT 2023 , Edited by admin on Sat Dec 16 00:32:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
MAJOR
PLASMA
|